One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease

The K-STAR Study

  • Lee, Chang Kyun MD, PhD
  • Moon, Won MD, PhD
  • Chun, Jaeyoung MD, PhD
  • Kim, Eun Soo MD, PhD
  • Kim, Hyung Wook MD, PhD
  • Yoon, Hyuk MD, PhD
  • Kim, Hyun Soo MD, PhD
  • Lee, Yoo Jin MD, MSc
  • Choi, Chang Hwan MD, PhD
  • Jung, Yunho MD, PhD
  • Park, Sung Chul MD, PhD
  • Song, Geun Am MD, PhD
  • Lee, Jong Hun MD, PhD
  • Jung, Eun Suk MD, PhD
  • Kim, Youngdoe PhD
  • Jung, Su Young Rph, PhD
  • Choi, Jong Min Rph, PhD
  • Ye, Byong Duk MD, PhD

  • Department of Gastroenterology, Center for Crohn’s and Colitis, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea

    Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

    Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

    Department of Internal Medicine, School of Medicine, Kyungpook National University, Korea

    Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea

    Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea

    Department of Internal Medicine, Chonnam University Medical School, Gwangju, Korea

    Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

    Department of Internal Medicine, College of Medicine, Chung-Ang University, Seoul, Korea

    Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea

    Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea

    Department of Internal Medicine, Pusan National University College of Medicine, Busan, Korea

    Department of Internal Medicine, Dong-A University Medical Center, Busan, Korea

    Medical Affairs, Janssen Korea Ltd., Seoul, Korea

    Medical Affairs, Janssen Korea Ltd., Seoul, Korea

    Medical Affairs, Janssen Korea Ltd., Seoul, Korea

    Medical Affairs, Janssen Korea Ltd., Seoul, Korea

    Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea

Address correspondence to: Byong Duk Ye, MD, PhD, Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. Tel: +82-2-3010-3181; Fax: +82-2-476-0824 ([email protected]).

Received December 20, 2023

Revised August 03, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory Bowel Diseases Publish Ahead of Print, August 03, 2024. | DOI: 10.1093/ibd/izae171

Lay Summary

Ustekinumab was well-tolerated and safe for Koran patients with Crohn’s disease with no new safety signal as induction and maintenance therapy. Biologic-naïve patients exhibited better effectiveness outcomes, whereas combination therapy with immunomodulators was not superior to ustekinumab monotherapy.

Copyright © Crohn's & Colitis Foundation